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Further advances are required in understanding protection from AIDS by T-cell immunity. We analyzed a
set of multigenic simian/human immunodeficiency virus (SHIV) DNA and fowlpox virus priming and boosting
vaccines for immunogenicity and protective efficacy in outbred pigtail macaques. The number of vaccinations
required, the effect of DNA vaccination alone, and the effect of cytokine (gamma interferon) coexpression by the
fowlpox virus boost was also studied. A coordinated induction of high levels of broadly reactive CD4 and CD8
T-cell immune responses was induced by sequential DNA and fowlpox virus vaccination. The immunogenicity
of regimens utilizing fowlpox virus coexpressing gamma interferon, a single DNA priming vaccination, or DNA
vaccines alone was inferior. Significant control of a virulent SHIV challenge was observed despite a loss of
SHIV-specific proliferating T cells. The outcome of challenge with virulent SHIVmn229 correlated with vaccine
immunogenicity except that DNA vaccination alone primed for protection almost as effectively as the DNA/
fowlpox virus regimen despite negligible immunogenicity by standard assays. These studies suggest that
priming of immunity with DNA and fowlpox virus vaccines could delay AIDS in humans.
In the absence of technologies to reliably induce broadly
neutralizing antibodies, protection against human immunode-
ficiency virus (HIV) relies on the clearance of already infected
cells by T-cell immunity (27). Heterologous priming and boost-
ing HIV vaccine strategies involving priming by DNA vaccina-
tion and boosting with recombinant attenuated pox virus vec-
tors (such as fowlpox virus) encoding common HIV or simian
immunodeficiency virus (SIV) antigens reliably induce high
levels of T-cell immune responses in outbred nonhuman pri-
mates (4, 17, 20, 22). Vaccine-induced simian/human immu-
nodeficiency virus (SHIV)-specific T-cell responses correlate
with partial protection from virulent SHIV infection (9). The
optimal use of these vaccines to protect humans from HIV-1
remains to be defined.
There are outstanding scientific and practical issues with this
vaccination approach. Although large peak CD8 T-cell re-
sponses are likely to be helpful, other qualities of T-cell im-
munity, such as the breadth, durability, presence, and timing of
CD4 T helper responses and recall immune response to infec-
tion may be equally important (19). Unadjuvanted DNA vac-
cination of outbred primates is often poorly immunogenic as
measured by current technologies, despite clearly priming for a
rapid expansion of T-cell immunity following recombinant pox
virus boosting (4, 22). Interestingly, pox virus vaccination alone
has, despite inducing lower levels of immune responses, been
reported to provide nearly similar immunity to DNA/pox virus
priming/boosting regimens in a rhesus/SHIV model (5).
High rates of viral mutation during early replication strongly
select for T-cell escape mutants and long-term protection from
lentiviral disease may be difficult to achieve with current, pri-
marily T-cell-based vaccines (8, 37). A potential problem as-
sociated with nonsterilizing protection from lentiviral disease is
the dysfunction and infection of virus-specific CD4 T-cell re-
sponses associated with HIV-1 infection (6, 7, 15). Only certain
subgroups of HIV-1-infected subjects, long-term nonprogres-
sors and those treated with antiretroviral therapy early in in-
fection, have preserved CD4 T-cell immune responses to
HIV-1 (16, 32). If CD4 T-cell dysfunction follows the blunted
burst of replication occurring in infected subjects with prior
T-cell immunity, this could abolish long-term protection from
disease.
Rhesus macaques selected for MamuA*01 major histocom-
patibility complex class I allele expression control virulent
SHIV89.6P infection following priming/boosting and other vac-
cination strategies (4, 9, 34). Protection is much poorer when
either SIVmac239 is used as the challenge virus or MamuA*01-
negative macaques are studied (38). We previously reported a
virulent mucosal HIV-1IIIB-based SHIVmn229 infection model
of outbred pigtail macaques (14). A codon-optimized SIVgag
DNA vaccine (previously shown to assist protection of
MamuA*01-positive rhesus macaques from SHIV89.6P disease)
(9) and virus-like-particle vaccines demonstrated poor protec-
tive immunity against a SHIVmn229 challenge in outbred pigtail
macaques (14). The SHIVmn229/pigtail macaque model could
provide a rigorous alternative model to study protective im-
munity of DNA and pox virus vaccines.
A disadvantage of priming/boosting vaccination strategies in
the field is the requirement for multiple different vaccinations.
Whether one DNA vaccination, in the absence of readily de-
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tectable immune responses, sufficiently primes specific T-cell
immune responses for augmentation by fowlpox virus boosting
and protection against a virulent challenge in nonhuman pri-
mates is not clear. In efforts to improve and further understand
the limitations of DNA/poxvirus priming/boosting regimens,
we studied multigenic SHIV DNA and fowlpox virus vaccines
for immunogenicity and protective efficacy in pigtail macaques.
Comparator regimens included DNA vaccination alone, a
fowlpox virus booster vaccine coexpressing gamma interferon
(IFN-), and a DNA/fowlpox virus regimen with a single DNA
priming.
MATERIALS AND METHODS
Monkeys. Juvenile Macaca nemestrina monkeys were free from HIV-1, SIV,
and simian retrovirus infection, housed under physical containment level 3 con-
ditions, and anaesthetized with ketamine (10 mg/kg intramuscularly) prior to
procedures. All experiments were performed according to National Institutes of
Health guidelines on the care and use of laboratory animals and were approved
by the University of Melbourne and CSIRO Livestock Industries Animal Exper-
imentation and Ethics committees.
DNA vaccinations. The DNA vaccine strain, pHIS-SHIV-B, encoded full-
length unmutated SIVmac239 Gag and Pol, HIV-1AD8, Tat, Rev, and Vpu, and the
5 third of HIV-1AD8 Env. Genes were inserted into vector pHIS-64 (Coley
Pharmaceutical Group, Wellesley, Mass.) behind the human cytomegalovirus
immediate-early promoter. Plasmid vector pHIS-64 has kanamycin resistance,
the bovine growth hormone poly(A) termination signal, and 64 CpG motifs in
addition to those naturally present that are primate optimized. Empty vector
plasmid DNA, pHIS, served as a control vaccine. Plasmid pHIS-SHIV-B for
immunization was prepared by Qiagen (Hilden, Germany), control DNA vaccine
pHIS was prepared with the EndoFree Plasmid Giga kit (Qiagen). Plasmid DNA
in normal saline was injected intramuscularly at 1 mg/ml at weeks 0 and 4 (Ta-
ble 1).
Recombinant fowlpox virus vaccines. Construction of the fowlpox virus vac-
cines has been described (11). Briefly, FPVgag/pol, expressing SIV Gag and Pol,
was constructed by inserting the promoter-SIV gag/pol PCR amplicon into
pKG10a for insertion into FPV-M3 at the F6,7,9 site. PCR primers for the
fowlpox virus early/late promoter and an early transcription terminator were
used for insertion into fowlpox virus vector FPV-M3. HIV-193TH254 env (mutated
to remove the middle third) was similarly amplified with fowlpox virus promoter
and terminator sequences and inserted into the plasmid vector pCH34 for con-
struction of a recombinant fowlpox virus with HIV Env expressed from the REV
insertion site. Human IFN– was inserted into FPV-SIVgag/pol under the con-
trol of the fowlpox virus early/late promoter immediately downstream of the
fowlpox virus thymidine kinase gene to construct vaccine FPV-SIVgag/pol-
IFN–, coexpressing human IFN–. Recombinants were selected on the basis of
coexpression of the Escherichia coli gpt gene and plaque purified on the basis of
coexpression of the E. coli -galactosidase gene. Fowlpox virus vaccines were
prepared in saline, and 5  107 PFU was injected intramuscularly at week 8
(Table 1).
IFN– Elispot assay. Enumeration of antigen-specific IFN–-secreting cells
was assessed with a monkey IFN– Elispot commercial kit (U-CyTech, Utrecht,
The Netherlands) as previously described (14). Briefly, freshly isolated periph-
eral blood mononuclear cells (PBMC) were stimulated with aldrithiol-2-inacti-
vated whole SIVmne or control microvesicles (5 g/ml, kindly provided by Jeff
Lifson, AIDS Vaccine Program, National Cancer Institute) or SIVmac239 Gag
and Pol overlapping 15-mer peptide pools (1 g/ml/peptide, supplied by the
National Institutes of Health AIDS Research and Reference Reagent Program)
for 18 h. Cells were washed twice, transferred to anti-IFN– monoclonal anti-
body-coated flat-bottomed 96-well plates containing antigen, and incubated for a
further 5 h. Cells were lysed, and plates were washed prior to incubation with
biotinylated anti-IFN- polyclonal rabbit antibody, followed by incubation with
gold-labeled anti-biotin immunoglobulin G antibody. IFN- spots were devel-
oped and analyzed by an automated reader (AID, Strassberg, Germany). Results
were normalized to antigen-specific IFN--secreting precursor frequency per 106
PBMC.
Intracellular IFN- staining. Induction of antigen-specific intracellular IFN-
expression in CD8 or CD3CD4 T lymphocytes was assessed by flow cytom-
etry as previously described (14, 25). Briefly, 200 l of whole blood was incubated
with 1 g/ml of overlapping 15-mer peptide pools in dimethyl sulfoxide or
dimethyl sulfoxide alone and the costimulatory antibodies CD28 and CD49d
(BD Biosciences Pharmingen, San Diego, Calif.) for 7 h. Brefeldin A (10 g/ml;
Sigma) was included during the last 5 h of the incubation. Anti-CD3-phyco-
erythrin, anti-CD4-fluorescein isothiocyanate, and anti-CD8-peridinin chloro-
phyll protein (BD) antibodies were added to each well and incubated for 30 min.
Red blood cells were lysed (fluorescence-activated cell sorting lysing solution;
BD) and washed with phosphate-buffered saline, and the remaining cells were
permeabilized (fluorescence-activated cell sorting permeabilizing solution 2;
BD). Permeabilized cells were then incubated with anti-human IFN--allophy-
cocyanin antibody (BD) prior to fixing with formaldehyde and acquisition (FAC-
Scan; BD). Acquisition data were analyzed with CellQuest (BD). The percentage
of antigen-specific gated lymphocytes expressing IFN- was assessed in both
CD3CD4 and CD3CD8 lymphocyte subsets.
Lymphoproliferative responses. Lymphoproliferative responses were assessed
by the standard [3H]thymidine incorporation assay to 1 g of SIV Gag peptide
pool per ml, 10 g of inactivated SIV per ml, or control antigens as described
(22) and also phenotyped by 5-(and 6)carboxyfluorescein diacetate,succinimidyl
ester (CFSE) proliferation studies. PBMC were stained with the fluorescent dye
CFSE (5 M; Molecular Probes, Eugene, Oreg.) prior to culturing for 6 days
with the SIVgag peptide pool or inactivated SIV as above. Cells were washed in
phosphate-buffered saline and phenotyped with monoclonal antibodies: phyco-
erythrin-conjugated anti-human CD3 (clone SP34; BD), peridinin chlorophyll
protein-conjugated anti-human CD4 (clone L200; BD), and allophycocyanin-
conjugated anti-human CD8 (clone Leu-2a; BD). Cells were formaldehyde fixed
before fluorescence-activated cell sorting analysis. Proliferating CD4 or CD8 T
cells were expressed as the percentage of CD3CD4 or CD3CD8 cells
emitting CFSE of a lower intensity than the CFSE intensity of the nondividing
T-lymphocyte subset.
SHIV challenge of macaques. To assess vaccine efficacy, all macaques were
inoculated atraumatically intrarectally with SHIVmn229 at 5  104 50% tissue
culture infectious doses (TCID50)/ml in 0.5-ml doses over 2 days (total, 105
TCID50/ml) as previously described (14). SHIV viremia was quantified by reverse
transcriptase real-time PCR, and depletion of peripheral CD4 T cells was quan-
tified by flow cytometry as described (14).
To further define the monkey infectious dose of the SHIVmn229 challenge
stock used (described in reference 14), the stock was further diluted and used for
intrarectal inoculation of M. nemestrina monkeys at doses of 2  102 and 2  103
TCID50. The two macaques used for each dilution of the stock became infected,
as evidenced by high viral load (mean peak SHIV plasma RNA for the four
animals, 7.9 log10 copies/ml; range, 7.6 to 8.7) and low peripheral CD4 T cells by
week 5 after inoculation (mean, 0.7% CD4 lymphocytes; range, 0.3 to 1.2%). The
administered dose of 105 TCID50 therefore represented a monkey infectious
dose of 500 TCID50.
TZM-bl luciferase reporter gene assay for neutralizing antibodies. Neutral-
ization was measured as a function of reductions in luciferase reporter gene
expression after a single round of virus infection in TZM-bl cells as described
(26). TZM-bl cells were obtained from the National Institutes of Health AIDS
Research and Reference Reagent Program, as contributed by John Kappes and
Xiaoyun Wu. These cells are engineered to express CD4 and CCR5 (28) and
contain integrated reporter genes for firefly luciferase and E. coli -galactosidase
under control of an HIV-1 long terminal repeat (39). Briefly, cell-free SHIVmn229
(200 TCID50, amplified on human PBMC) was incubated with serial dilutions of
test samples in triplicate in a total volume of 150 l for 1 h at 37°C in 96-well
flat-bottomed culture plates. Freshly trypsinized cells (10,000 cells in 100 l of
growth medium containing 75 g of DEAE dextran per ml and 2.5 M indinavir)
were added to each well. One set of control wells received cells and virus (virus
control), and another set received cells only (background control). After a 48-h
incubation, 100 l of cells was transferred to 96-well black solid plates (Costar)
for measurements of luminescence with Bright Glo substrate solution as de-
scribed by the supplier (Promega). Neutralization titers are the dilution at which
relative luminescence units were reduced by 50% compared to virus control wells
after subtraction of background relative luminescence units.
TABLE 1. Vaccine and challenge regimens
Vaccine
regimen
No. of
monkeys
Immunization regimen
Wk 0 Wk 4 Wk 8 Wk 18
Control 6 Control Control Control SHIV challenge
2DNA/FPV 6 DNA DNA FPV
1DNA/FPV 6 DNA FPV
3DNA 6 DNA DNA DNA
2DNA/FPV-IFN- 6 DNA DNA FPV-IFN-
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Power and statistical considerations. The primary endpoints, set prior to
starting the study, were differences in outcome of SHIV challenge (peak and set
point SHIV viremia and set point peripheral CD4 T-cell levels) between groups.
Based on previous studies with this challenge stock (14), six macaques per group
powered the study (80%, 2  0.05) to detect 0.5 log10 differences in both peak
(week 2) and set point (mean, of weeks 5 to 11) plasma SHIV RNA and 5% set
point CD4 T lymphocytes between groups. Comparison of viral load at set point
utilized a time-weighted area-under-the-curve analysis. Week 11 was chosen as
the end of the set point time period based on previous studies (14), as all
macaques were likely to be alive and contributing data points up to that time, but
at least some control macaques were likely to be euthanized shortly thereafter.
Statistical comparisons of secondary endpoints of immunogenicity between vac-
cine groups utilized a t test of pairwise comparisons without compensation for
the multiple analyses performed.
RESULTS
T-cell immunogenicity. The kinetics, magnitude, and pheno-
type of the cellular response induced by vaccination was quan-
tified by antigen-specific T-cell expression of IFN- by Elispot
(Fig. 1) and intracellular IFN- staining (Fig. 2) assays. The
2DNA/FPV vaccine regimen was the most immunogenic, in-
ducing a mean peak response to SIV Gag peptides of 797
spot-forming cells/106 PBMC (range, 455 to 1345) 1 week after
the fowlpox virus booster was administered (Fig. 1A). Simi-
larly, the mean response to whole inactivated SIV peaked at
1,005 spot-forming cells/106 PBMC (range, 595 to 1400) at
week 9, demonstrating vigorous recognition of processed viral
particles (Fig. 1B). Despite the small number of IFN--secret-
ing T cells after DNA vaccination (mean response to Gag
peptides at week 8, 75 spot-forming cells/106 PBMC; range, 25
to 215), a rapid rise within 1 week of the fowlpox virus booster
indicated that the DNA vaccine induced effective priming of
the cellular response. All other vaccine groups also exhibited
significantly elevated SIV Gag responses relative to controls 1
week after the final vaccination (P 	 0.05).
Modification of the 2DNA/FPV vaccination regimen in-
duced lower numbers of antigen-specific cells. Coexpression of
IFN- from the fowlpox virus construct had the undesired
effect of reducing the peak number of IFN--secreting T cells
in response to inactivated SIV and Gag peptides by 51% (P 
0.01) and 40% (P  0.13), respectively. Similarly, administra-
tion of a single DNA vaccination prior to the fowlpox virus
booster reduced the response to inactivated SIV and SIV Gag
relative to the 2DNA/FPV regimen by 44% (P  0. 055) and
54% (P  0.11), respectively. Three DNA vaccinations alone
induced much lower levels of IFN--expressing cells (122 and
192 cells/106 PBMC to Gag peptides and whole SIV, respec-
tively; both, P 	 0.01 compared to 2DNA/FPV).
Responses to the polymerase region of SIV were substan-
tially lower than observed for the other antigens (Fig. 1C),
presumably reflecting the lower level of polymerase expression
from the vaccines. The only vaccine group to exhibit a poly-
merase response above background levels was the 2DNA/FPV
regimen for a period of 3 weeks after the booster (P 	 0.05 at
week 9).
The Gag response in 2DNA/FPV vaccine recipients was
further characterized at peak response for the breadth of the
response (Fig. 1D). Stimulation with pools of 10 SIV Gag
peptides showed that the response across the Gag region was
broad in most animals with responses of 
50 spots/106 PBMC
generated to an average of four pools (range, two to seven
pools).
The immunogenicity of all vaccine regimens was phenotyped
by intracellular IFN- staining for IFN--expressing CD4 and
FIG. 1. Time course of mean cellular immune responses and stan-
dard error, as determined by IFN- Elispot in groups of six macaques
immunized with F 2DNA/FPV, 2DNA/FPV-IFN-, } 1DNA/FPV,
3DNA, and E control vaccines in response to activation with (A)
SIV Gag peptide pool, (B) aldrithiol-2-inactivated SIV, and (C) poly-
merase peptide pool. The breadth of the SIV Gag 125-peptide pool
response at week 9 was further characterized for the six 2DNA/FPV-
vaccinated macaques by (D) assessing responses in sequential 10-
peptide pools.
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CD8 T cells and the kinetic pattern of CD4 and CD8 T-cell
responses was studied weekly in the 2DNA/FPV group early
following the fowlpox virus boost (Fig. 2). Peak numbers of
Gag-specific CD4 T cells occurred 1 week after the fowlpox
virus booster. CD4 T-cell responses were highest in the 2DNA/
FPV-vaccinated group (1.0% of CD3CD4 lymphocytes;
range, 0.2 to 2.1%) and reduced in other vaccine groups.
The frequency of Gag-specific CD8 T cells was higher than
Gag-specific CD4 T cells, peaking at 2.4% (range, 0.3 to 4.7%)
of all CD8 T cells in the 2DNA/FPV-vaccinated group. The
peak SIV Gag-specific CD8 T-cell response in these animals
occurred 1 week later than the peak CD4 T-cell response. All
other comparator vaccine regimens generated substantially
lower CD8 T cells expressing IFN-. The difference in magni-
tude of Gag-specific CD8 T-cell responses between groups
detected by intracellular IFN- staining was exaggerated com-
pared with CD4 T-cell responses by intracellular IFN- stain-
ing and T-cell immunogenicity by IFN- Elispot.
Lymphoproliferation studies. To assess the proliferative ca-
pacity of SIV-specific CD4 and CD8 T cells, lymphoprolifera-
tive responses were analyzed with both the [3H]thymidine in-
corporation assay and a CFSE proliferation assay. A 6-day
culture of CFSE-stained PBMC isolated from a macaque im-
munized with the 2DNA/FPV vaccine regimen 2 weeks after
fowlpox virus boosting had a large proportion of CD4 T cells
proliferating in response to both SIV Gag peptides and inac-
tivated SIV stimulation (Fig. 3). Although responses were
lower, CD8 T cells also proliferated to the SIV antigens.
When analyzed across the different vaccine regimens, pro-
liferative SIV Gag-specific CD4 T cells early after fowlpox
virus boosting were greatest in macaques immunized with the
2DNA/FPV regimen, with lower responses in the 1DNA/FPV
and 2DNA/FPV-IFN- regimens and negligible Gag-specific
proliferative responses in the 3DNA regimen (Fig. 3), similar
to the pattern of T-cell immune responses observed by IFN-
Elispot and intracellular IFN- staining. A similar pattern of
proliferative responses to both SIV Gag peptides and inacti-
vated SIV was observed by the [3H]thymidine incorporation,
with the exception that the responses in the 2DNA/FPV-IFN-
immunized group were equivalent to those of the 2DNA/FPV
group.
SHIV challenge. The pathogenic SHIVmn229 challenge stock
was inoculated intrarectally (105 TCID50 or 500 monkey in-
fectious doses) into all 30 macaques 10 weeks after the last
vaccination. CD4 T cells and plasma SHIV RNA were fol-
lowed for 33 weeks, unless macaques were euthanized to avoid
AIDS-related illnesses (Fig. 4). The six control macaques re-
ceiving DNA and fowlpox virus vaccines not expressing SHIV
antigens had high peak levels of SHIV RNA (mean, 8.2 log10
copies/ml; Table 2) following inoculation and at set point
(weeks 5 to 11; mean, 6.2 log10 copies/ml; Fig. 4B). All six
control macaques lost peripheral CD4 T cells precipitously,
declining to a mean of 0.43% of total lymphocytes 3 weeks
after challenge, and five of the six macaques were euthanized
within 15 weeks of inoculation with incipient AIDS.
All 24 vaccinated macaques became infected except one in
the 1DNA/FPV group (animal 4237). Peak SHIV viral load in
the infected macaques at 2 weeks following inoculation was
lowest in the groups vaccinated with the 2DNA/FPV and
3DNA regimens (means, 6.7 log10 copies/ml), being signifi-
cantly lower than controls (Fig. 4A, Table 2). The peak viral
load in the 2DNA/FPV-IFN- regimen (mean, 7.3 log10 copies/
ml; Table 2) was also lower than controls, and the peak viral
load in the 1DNA/FPV regimen, excluding the outlier animal
4237 that did not become infected, was not significantly differ-
ent from controls (mean, 7.4 log10 copies/ml). There were no
significant differences in viral load between the vaccinated
groups.
Set point viral load was defined prior to challenge as the
mean viral load over weeks 5 to 11 following challenge, when
viral load is relatively stable and all animals appear healthy. Set
point SHIV viral load was lowest in the groups vaccinated with
the 2DNA/FPV and 3DNA regimens (4.9 and 4.8 log10 copies/
ml, respectively), being significantly lower than controls and
the 1DNA/FPV regimen (6.2 and 6.0 log10 copies/ml, respec-
tively; Fig. 4A, Table 2). The set point viral load in the 2DNA/
FPV-IFN- regimen (5.6 log10 copies/ml) was not significantly
different from that of controls.
FIG. 2. Immunogenicity of vaccine regimens as shown by flow cy-
tometric analysis of intracellular IFN- staining. Time course of mean
CD8IFN- and CD4IFN- Gag-specific T cells ( standard er-
ror of the mean) in groups of macaques immunized with F 2DNA/
FPV, 2DNA/FPV-IFN-, } 1DNA/FPV, 3DNA, and E control
vaccines.
13822 DALE ET AL. J. VIROL.
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
There was significant retention of peripheral CD4 T cells in
the groups immunized with the 2DNA/FPV regimen at set
point levels between weeks 5 and 11 (mean, 12.3% CD4 T
lymphocytes) compared to controls (0.5%), the 1DNA/FPV-
vaccinated group (1.8%), and the 2DNA/FPV-IFN--vacci-
nated group (2.3%; Fig. 4A, Table 2). The 3DNA-vaccinated
group also showed significant retention of CD4 T lymphocytes
(11.7%) compared to controls (Table 2).
The animals were followed for 33 weeks following SHIV
challenge (Fig. 4B to F). Five animals in the 2DNA/FPV-
IFN- group, four in the 1DNA/FPV group, two in the 3DNA
group, and none in the 2DNA/FPV group were euthanized
with incipient AIDS within 18 weeks after SHIV challenge.
Only 2 of the 29 infected macaques controlled viremia to below
detectable levels (one in each of the 3DNA and 2DNA/FPV-
IFN- groups), with all the remaining macaques experiencing
ongoing viremia. Peripheral CD4 T cells were retained (
10%
of lymphocytes) at the end of the study in four of the 2DNA/
FPV-immunized animals, three of the 3DNA-immunized ani-
mals, and only one each of the 1DNA/FPV- and 2DNA/FPV-
IFN--immunized animals.
The partial protection in the group receiving the 3DNA
vaccines in the absence of significant T-cell immunity as a
group was interesting, and we therefore attempted to correlate
the outcome of challenge with prechallenge T-cell immune
responses across all animals in all groups. There was a weak
but significant correlation between peak CD8 T-cell responses
to SIV Gag as measured by intracellular IFN- staining with
set point viral load (r0.38, P 0.05, Fig. 5) and CD4 T-cell
count (r  0.47, P  0.01). However, reductions in peak viral
load did not correlate with any T-cell immunity parameter
studied, and SIV Gag-specific CD4 T-cell responses by intra-
cellular IFN- staining or SIV-specific immunity as measured
by Elispot did not correlate with outcome of challenge (not
shown). The three animals in the 3DNA immunization group,
which effectively controlled the SHIVmn229 challenge, did not
have high levels of T-cell immunity (Fig. 5, grey squares).
Immune responses following challenge. T-cell immunity was
analyzed following SHIV challenge by intracellular IFN-
staining and proliferation studies (Fig. 6). SIV Gag-specific
CD8 T cells expressing IFN- were dramatically boosted after
challenge (Fig. 6A). Mean Gag-specific CD8 T cells peaked 3
weeks following challenge at 11.7% (range, 3.0 to 34.7%) of all
CD8 T cells in these outbred pigtail macaques immunized with
the 2DNA/FPV regimen. The other vaccine groups had lower
mean postchallenge CD8 T-cell responses, with peak responses
at week 2 following challenge numbering 3.8% (range, 0.1% to
9.5%) in the 3DNA group, 1.1% (range, 0% to 4.0%) re-
sponses in the 1DNA/FPV group, and 2.0% (range, 0% to
6.2%) in the 2DNA/FPV-IFN--immunized animals.
FIG. 3. Lymphoproliferative responses postimmunization. (A) CFSE-labeled PBMC obtained 2 weeks following fowlpox virus boosting were
incubated with either SIV Gag peptides or inactivated SIV and the corresponding controls (dimethyl sulfoxide and microvesicles, respectively).
Proliferating PBMC were phenotyped, and the CD4 and CD8 proliferative responses were detected in one macaque immunized with the SHIV
vaccines are shown. The shaded peak (grey) shows the background proliferation to control antigens, and the solid line shows the proliferating cells.
The percentage of cells proliferating is indicated in each histogram. (B) Mean ( standard error) proliferation responses are shown for each group
postimmunization with the fowlpox virus vaccines. Proliferation responses for CD4 and CD8 T cells are shown for CFSE-labeled PBMC in
response to SIV Gag peptides (mean of four macaques per group, left panel) and the standard [3H]thymidine incorporation method to both SIV
Gag overlapping peptides and whole inactivated SIV (mean of six macaques per group, right panel).
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A substantial postchallenge increase in IFN--expressing
Gag-specific CD4 T cells was also observed in some vaccinated
macaques after SHIV challenge, despite at least some deple-
tion of total CD4 T cells in almost all animals (Fig. 6B). In the
2DNA/FPV group, a gradual rise in the proportion of SHIV-
specific CD4 T cells expressing IFN- occurred, reaching a
mean of 1.9% (range, 0.2% to 3.8%) by 15 weeks after chal-
lenge. Data were not available for macaques in other groups at
time points when there were too few macaques (less than three
out of six) with sufficient peripheral CD4 T cells (
1%) to
estimate the mean number of SHIV-specific CD4 T cells. De-
spite these limitations, a significant proportion of CD4 T cells
was expressing IFN- in response to Gag stimulation in the
3DNA group, the 1DNA/FPV group, and (at 1 week after
challenge) the 2DNA/FPV-IFN- group.
In contrast to the large anamnestic SHIV-specific CD4 and
CD8 T cells expressing IFN- in response to SHIV challenge,
there was a nearly complete lack of SHIV-specific proliferating
T cells (Fig. 6C). Proliferating T cells were readily detected up
to 5 weeks after the last vaccination in the 2DNA/FPV, 1DNA/
FPV, and 2DNA/FPV-IFN- groups, but no significant rise in
SHIV-specific proliferating T cells was observed out to 15
weeks after challenge. This lack of anamnestic proliferation
response to virus challenge was observed with both inactivated
SIV as a stimulating antigen (Fig. 6C) and SIV Gag peptides
(not shown).
Since the partial control of SHIV89.6P viremia in previous
DNA and pox virus vaccine studies has been associated with a
rapid rise in neutralizing antibodies (4), we assessed neutral-
izing antibody responses to SHIVmn229 following challenge.
There were no neutralizing antibodies to SHIVmn229 at the
time of challenge (consistent with the divergent and mutated
env genes in the vaccines) and no significant neutralizing an-
tibody responses developed prior to week 11 postchallenge
(Fig. 6D). At week 11 (when all animals were still alive), higher
neutralizing antibody responses were detected in the 2DNA/
FPV group compared to controls or the other vaccine groups.
DISCUSSION
This study demonstrated high levels of CD4 and CD8 T-cell
immunity in outbred pigtail macaques immunized with DNA
and FPV vaccines. Partial protective immunity was observed
following a very high dose, virulent SHIVmn229 mucosal chal-
lenge. Comparator regimens that used a single DNA priming
vaccination or coexpressed IFN- with the fowlpox virus boost
were less immunogenic and less protective. A vaccine regimen
that utilized only the DNA vaccine demonstrated reasonable
protective efficacy despite being far less immunogenic than the
DNA/fowlpox virus regimens.
The protection observed in the DNA vaccination alone
group is intriguing. Little or no SHIV-specific CD4 or CD8
T-cell response was induced by DNA vaccination alone by
IFN- Elispot, intracellular cytokine staining, or proliferation
studies. Although there was a weak but significant inverse
correlation across all animals between set point viral load and
SIV Gag-specific CD8 T cells, this correlation was primarily
driven by high levels of immunity in animals receiving the
2DNA/FPV vaccines. Levels of T-cell immunity were low in
animals receiving 3DNA immunizations that controlled the
SHIVmn229 challenge. Following challenge, a sharp rise in CD8
and CD4 T-cell responses was observed in the 3DNA vaccina-
tion group, parallel to but lower than those observed in the
2DNA/FPV group. Mean viral load and CD4 counts were
FIG. 4. Outcome of SHIVmn229 challenge. Each macaque was chal-
lenged intrarectally with a monkey infectious dose of 500 SHIVmn229
10 weeks post-final immunizations. Blood samples were analyzed for
plasma SHIV RNA by real-time PCR and for CD4 T-cell loss. (A)
Mean (standard error of the mean) plasma SHIV RNA and CD4 T
cells for each vaccine group. (B to F) Plasma SHIV RNA and CD4
T-cell responses are shown for individual macaques grouped for each
vaccine regimen.
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indistinguishable from the 2DNA/FPV group for the first 11
weeks postchallenge, which were the primary endpoints. These
results suggest that the “priming” effect of the DNA vaccine
alone may be sufficient to recall effective immune responses
following challenge. The priming of immunity by the DNA
vaccine may have been assisted by the multiple immunostimu-
latory CpG motifs added to the vector and expression of a
large proportion of SHIV antigens. These results raise ques-
tions about whether the expansion (and contraction) of T cells
following the boosting poxvirus vaccination is either required
or useful for long-term protective immunity (10). Technologies
to more readily measure and characterize this priming immune
response following DNA vaccination could facilitate a better
understanding of protective T-cell immunity.
The poorer SHIV-specific immunity in the DNA/fowlpox
virus group coexpressing IFN- confirmed data in macaques
with similar HIV-1 vaccines (Dale et al., submitted for publi-
cation). Not only were T-cell responses significantly lower in
animals vaccinated with fowlpox virus coexpressing IFN-, but
a nearly complete loss of protective efficacy was observed. We
hypothesize that the expression of IFN- may downregulate
fowlpox virus vector expression of the inserted SHIV genes.
This is supported by findings in a previous study where altered
anti-fowlpox virus antibody responses were observed after
boosting with cytokine coexpressing fowlpox virus vaccines
(Dale et al., submitted).
Several phenotypic features of the T-cell responses induced
by these DNA and fowlpox virus vaccines were of interest.
Serial weekly measurements of SHIV-specific CD4 and CD8
T-cell responses by intracellular IFN- staining demonstrated
a coordinated early induction of CD4 responses of lower mag-
nitude 1 week following the boost and then later induction of
CD8 responses of higher magnitude 2 weeks following the
boost. Multiple regions of SIV Gag were recognized by the
T-cell responses induced as detected by both IFN- Elispot
(Fig. 1D) and intracellular IFN- staining assays (not shown).
Additional analyses of the T-cell responses induced by these
vaccines are ongoing, including epitope mapping, analyzing
memory markers, defining additional cytokines secreted by
specific T cells, and examining the in vivo cytotoxic potential of
the immunity induced.
The vaccinations did not induce significant envelope-specific
T-cell responses (not shown) likely because of the truncated
and heterologous Env proteins expressed by these DNA and
fowlpox virus vaccines. SIV Gag-specific antibody responses
were induced by the vaccines, but no significant antibody re-
sponse to envelope was detected prechallenge (unpublished
data; Dale et al., submitted) and no significant neutralizing
antibody responses were detected at the time of challenge.
Improving expression of whole Env antigens may also facilitate
at least narrowly directed neutralizing antibody responses. Re-
sponses to polymerase were lower than to Gag, consistent with
lower expression of polymerase by the vaccines (Purcell et al.,
unpublished data). Improvement in expression of polymerase
proteins could potentially improve the breadth of immune
responses induced by these vaccines.
Several aspects differentiated this study from previous DNA
prime/poxvirus boost macaque studies (2, 4, 17, 18, 22, 23, 29,
31, 33). First, we studied outbred, unselected pigtail macaques
that were highly susceptible to SHIV infection. Second, we
used a pathogenic, high-dose, intrarectal SHIVmn229 challenge
and demonstrated partial protection. In contrast to SHIV89.6P
challenge of vaccinated MamuA*01-positive rhesus macaques
(4, 9, 34), few (3 out of 24) vaccinated pigtail macaques chal-
FIG. 5. Correlation between CD8 T immune responses induced by
immunization and outcome of challenge—set point viral load at week
11. The 30 individual macaques are from the five vaccination regimens
are indicated by the symbols: F 2DNA/FPV, 2DNA/FPV-IFN-,
} 1DNA/FPV, 3DNA, and E controls.
TABLE 2. Outcome of SHIVmn229 viral challenge
Group
SHIVmn229 viral load
% CD4 CD3 T cells
at set pointPeak viral load
(log10 copies/ml)
Set pointa viral load
(log10 copies/ml)
Mean Range P
b vs.
controls Mean Range
P
Mean Range
P
Vs.
controls
Vs. 2DNA/
FPV
Vs.
3DNA
Vs.
controls
Vs. 2DNA/
FPV
Vs.
3DNA
Control 8.2 7.8–8.6 6.2 5.4–6.7 0.5 0.05–2.0
2DNA/FPV 6.7 5.1–7.9 0.004 4.9 4.4–5.4 0.002 12.3 0.7–21.5 0.006
3DNA 6.7 4.7–8.2 0.016 4.8 3.8–6.0 0.011 0.785 11.4 0.6–22.6 0.033 0.92
1DNA/FPV 7.4 5.9–8.6 0.09 5.95 5.3–6.6 0.565 0.006 0.031 1.8 0.1–4.2 0.154 0.023 0.082
2DNA/FPV-IFN- 7.4 6.6–8.2 0.02 5.6 4.0–6.5 0.224 0.107 0.139 2.3 0.1–8.7 0.216 0.021 0.073
a Set point values taken from weeks 5, 8, and 11 postchallenge.
b P represents the P value for pairwise comparisons between the group noted and the other vaccine groups.
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lenged with SHIVmn229 completely controlled viremia. Homol-
ogous neutralizing antibody responses to SHIVmn229 were not
rapidly (8 weeks) generated following challenge, which is
also in contrast to SHIV89.6P challenge studies. The slow gene-
ration of neutralizing antibody to SHIVmn229 is consistent with
the long (30 to 70 weeks) initial in vivo passage of SHIVHXB2
through two pigtail macaques, the heterologous nature of the
neutralization determinants in the vaccines, and the previously
described resistance to neutralizing antibody of pathogenic
SHIVs derived from SHIVHXB2 (1, 12, 13, 21, 35, 36, 41). The
late generation of neutralizing antibody (11 weeks postchal-
lenge) did not completely control SHIVmn229 viremia in these
animals, potentially due to evolution of neutralizing antibody
escape variants over time, as described in humans with HIV-1
infection (30, 40). Ongoing viral replication observed following
the acute infection is also highly likely to select for T-cell
escape variants and eventual loss of viral control in this model,
as observed in SIVmac239/rhesus macaque studies (38).
Following SHIV challenge, SHIV-specific IFN--secreting
CD4 T-cell responses were detected in animals with partial
control of viremia. Interestingly, few or no SHIV-specific T
cells could be detected by proliferation studies, suggesting that
SHIV-specific CD4 T cells were dysfunctional. In vitro SHIV
infection in the culture could have killed proliferating T cells,
although additional experiments with antiretroviral drug treat-
ment in vitro did not rescue T-cell proliferative capacity (not
shown). A proliferative defect in HIV-1-specific T cells is
common in humans chronically infected with HIV-1, and
HIV-1-specific CD4 T cells appear to be preferential targets
for infection and elimination by HIV-1 (15). The long-term
effectiveness of HIV-1 vaccines that induce nonsterilizing im-
munity could be limited by infection-induced dysfunction of
HIV-specific T cells (10).
These studies have been used to guide subtype B-based
HIV-1 DNA and fowlpox virus clinical vaccine studies in Aus-
tralia that use the 2DNA/FPV vaccine regimen. The SHIV DNA
vaccine component studied herein expressed six SHIV genes,
while the fowlpox virus SHIV vaccines expressed only three,
and one of these (Env) was derived from a different HIV-1
strain. Recent studies suggest including additional shared SHIV
genes, in particular that for the envelope, can facilitate the
induction of broadly reactive T-cell immunity (3, 24). In order
to evaluate whether improved DNA/FPV vaccine combina-
tions can generate broader immunity, our group has now con-
structed single recombinant FPV for both HIV-1 (based on
HIV-1 subtype A/E) and SHIV that express nearly identical
large amounts of antigenic material. Plans are under way in
2004 to evaluate an HIV-1 A/E DNA/fowlpox virus combina-
tion in clinical trials in Thailand.
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